肿瘤诱发的骨软化症（TIO）属于副肿瘤综合征的一种罕见疾病。磷酸尿间质瘤（PMT）是TIO最常见的原因，但不能排除其他肿瘤的可能性。我们介绍了一名36岁女性全身骨骼异常患者的病例。该妇女抱怨腰痛并伴有轻度运动功能障碍已有两年。实验室检查显示骨代谢标志物、甲状旁腺激素（PTH）、维生素D和血清磷异常。合并影像学检查显示骨骼系统存在伸展异常，右侧股骨头存在单一病变。右侧股骨病变影像学显示生长抑素受体阳性，高度提示单个神经内分泌肿瘤。内科治疗无效后行CT引导下右股骨肿瘤切除植骨术。术后病理诊断为分泌成纤维细胞生长因子23（FGF23）的磷酸尿间质瘤，符合术前预期。术后症状得到有效缓解，指标恢复正常。引起TIO的肿瘤在组织来源、病理特征和生物学行为方面表现出显着的异质性，但独特的共同特征是FGF23的分泌。随着诊断和治疗的显着进展，大多数TIO患者的临床随访显示预后良好，但恶性肿瘤患者的预后相对较差。© 2023 The Authors.天津医院与John Wiley联合出版的《骨科外科》

Tumor-induced osteomalacia (TIO) belongs to a rare disease of the paraneoplastic syndrome. Phosphate uric mesenchymal tumor (PMT) is the most common cause of TIO, while the possibility of other tumors cannot be excluded.We present a case of a 36-year-old female patient with systemic skeletal abnormalities. The woman complained of low back pain with mild motor dysfunction for 2 years. Laboratory examination showed abnormalities in markers of bone metabolism, parathyroid hormone (PTH), vitamin D and serum phosphorus. Pooled imaging examination indicated extension abnormalities in the skeletal system and a single lesion in the right femoral head. The lesion of the right femoral was imaging with somatostatin receptor-positive, which was highly suggestive of a single neuroendocrine tumor. CT guided right femoral tumorectomy and bone grafting were performed when medical treatment failed. Postoperative pathological diagnosis was phosphate urinary mesenchymal tumor secreting fibroblast growth factor 23 (FGF23), which accorded with pre-operative expectations. The postoperative symptoms were effectively relieved, and indicators returned to normal.The tumors causing TIO exhibited significant heterogeneity in terms of tissue origin, pathological characteristics and biological behavior, but the unique common characteristic is the secretion of FGF23. With significant progress in diagnosis and treatment, the clinical follow-up of most TIO patients shows a good prognosis, but the prognosis of those with malignant tumors is relatively poor.© 2023 The Authors. Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.